Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

BridgeBio raises $1B via preferred equity from Sixth Street and KKR's HealthCare Royalty, stockpiling cash ahead of three drug launches within 18 months.